Retatrutide: a triple incretin receptor agonist for obesity management
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Retatrutide: a triple incretin receptor agonist for obesity management
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-6
Publisher
Informa UK Limited
Online
2023-10-30
DOI
10.1080/13543784.2023.2276754
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5
- (2023) Sean Wharton et al. Obesity
- Evidence for a lack of inotropic and chronotropic effects of glucagon and glucagon receptors in the human heart
- (2023) Ramón Aranda-Domene et al. Cardiovascular Diabetology
- The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying
- (2023) Shweta Urva et al. DIABETES OBESITY & METABOLISM
- Contemporary medical, device, and surgical therapies for obesity in adults
- (2023) Carolina M Perdomo et al. LANCET
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
- (2023) Juan P Frias et al. LANCET
- Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment
- (2023) Jacob Levi et al. Obesity
- Glucagon and exenatide improve contractile recovery following ischaemia/reperfusion in the isolated perfused rat heart
- (2023) Ross T. Lindsay et al. Physiological Reports
- The role of mitochondria in myocardial damage caused by energy metabolism disorders: From mechanisms to therapeutics
- (2023) Ao-lin Li et al. FREE RADICAL BIOLOGY AND MEDICINE
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
- (2023) W Timothy Garvey et al. LANCET
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
- (2023) Julio Rosenstock et al. LANCET
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
- (2023) Mikhail N. Kosiborod et al. NEW ENGLAND JOURNAL OF MEDICINE
- Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
- (2023) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial
- (2022) Charlotte C. van Ruiten et al. PSYCHONEUROENDOCRINOLOGY
- SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy
- (2022) Stefan D. Anker et al. CIRCULATION
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Shifting Tides Offer New Hope For Obesity
- (2022) Clifford J. Rosen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial
- (2022) Daniel Maselli et al. Obesity
- Role of the Gut Microbiota in Glucose Metabolism During Heart Failure
- (2022) Pei Bao et al. Frontiers in Cardiovascular Medicine
- Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents
- (2022) Caroline E. Geisler et al. DIABETES OBESITY & METABOLISM
- Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control
- (2022) Ryan J. Jalleh et al. DIABETOLOGIA
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2022) Melanie J. Davies et al. DIABETOLOGIA
- Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
- (2022) Patrick J. Knerr et al. Molecular Metabolism
- Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity
- (2022) Joana Nicolau et al. PHYSIOLOGY & BEHAVIOR
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The evolving story of incretins ( GIP and GLP ‐1) in metabolic and cardiovascular disease: A pathophysiological update
- (2021) Michael A. Nauck et al. DIABETES OBESITY & METABOLISM
- The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists
- (2020) Shweta Urva et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
- (2020) Laurie L. Baggio et al. Molecular Metabolism
- Targeting the glucagon receptor improves cardiac function and enhances insulin sensitivity following a myocardial infarction
- (2019) Qutuba G. Karwi et al. Cardiovascular Diabetology
- SGLT2 inhibition and glucagon secretion in humans
- (2018) C. Saponaro et al. DIABETES & METABOLISM
- Insulin and Glucagon: Partners for Life
- (2017) Jens Juul Holst et al. ENDOCRINOLOGY
- Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist
- (2016) Nicolas Damond et al. eLife
- Glucagon receptor gene deletion in insulin knockout mice modestly reduces blood glucose and ketones but does not promote survival
- (2016) Ursula H. Neumann et al. Molecular Metabolism
- Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
- (2015) V. Salem et al. DIABETES OBESITY & METABOLISM
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incretin hormones and the satiation signal
- (2013) J J Holst INTERNATIONAL JOURNAL OF OBESITY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started